Efficacy

Efficacy of Retsevmo (selpercatinib) in Lung Cancer

Retsevmo, known by its generic name selpercatinib, is a medication specifically designed to target RET (rearranged during transfection) gene alterations. In the context of lung cancer, selpercatinib has demonstrated efficacy in treating non-small cell lung cancer (NSCLC) that is RET fusion-positive. Clinical trials have shown that selpercatinib can achieve significant responses in patients with RET fusion-positive NSCLC who were previously treated with platinum chemotherapy, as well as in those who were treatment-naive. The response rate and duration of response observed in these studies suggest that selpercatinib is a potent and effective option for this subset of lung cancer patients.

The approval of Retsevmo for the treatment of RET fusion-positive NSCLC was based on the results of the LIBRETTO-001 trial, which showed a high objective response rate (ORR) in patients treated with selpercatinib. This included patients with central nervous system (CNS) involvement, indicating that selpercatinib has activity against tumors that have spread to the brain, which is a common and challenging aspect of lung cancer management. The safety profile of selpercatinib was also considered manageable, with most adverse events being of low grade.

Efficacy of Xalkori (crizotinib) in Lung Cancer

Xalkori, with the generic name crizotinib, is another targeted therapy that has shown efficacy in the treatment of NSCLC, specifically in patients whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive. Crizotinib is a small molecule tyrosine kinase inhibitor that targets ALK and ROS1, which are genetic alterations that can drive the growth of cancer cells. In clinical trials, crizotinib has demonstrated high response rates in patients with ALK-positive NSCLC, leading to its approval as a first-line treatment for this particular genetic subtype of lung cancer.

The PROFILE 1014 study, which compared crizotinib to chemotherapy in previously untreated ALK-positive NSCLC patients, showed a significant improvement in progression-free survival (PFS) for those treated with crizotinib. Additionally, crizotinib has been found to have activity against CNS metastases, similar to selpercatinib, which is particularly important in lung cancer treatment. While the efficacy of crizotinib in ROS1-positive NSCLC is based on a smaller subset of patients, the results have been similarly promising, with high response rates and durable responses. As with selpercatinib, the side effect profile of crizotinib is considered manageable, although it may include some unique adverse events such as visual disturbances.